Metabolic and mitochondrial disorders associated with epilepsy in children with autism spectrum disorder

Epilepsy and Behavior

Volumn 47, Issue , 2015, Pages 147-157

  Frye, Richard E ^a,b  

^a ARKANSAS CHILDREN S HOSPITAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Autism; Cerebral folate deficiency; Comorbidities; Epilepsy; Metabolic disorders; Mitochondrial disease; Mitochondrial dysfunction

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BIOTIN; CARNITINE; CARNOSINE; CHOLESTEROL; CORTICOTROPIN; MAGNESIUM; MECOBALAMIN; PLACEBO; PYRIDOXINE; QUINONE DERIVATIVE; UBIDECARENONE; UBIQUINOL; UNCLASSIFIED DRUG; VITAMIN B GROUP;

ADENYLOSUCCINATE LYASE DEFICIENCY; AUTISM; BIOTINIDASE DEFICIENCY; CARNITINE DEFICIENCY; CLINICAL FEATURE; COMORBIDITY; DIET THERAPY; DISEASE ASSOCIATION; DISORDERS OF CHOLESTEROL METABOLISM; DISORDERS OF CREATINE METABOLISM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG RESPONSE; EPILEPSY; FOLIC ACID DEFICIENCY; GENE MUTATION; HUMAN; HYPERURICOSURIC AUTISM; METABOLIC DISORDER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PHENYLKETONURIA; PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE DEFICIENCY; POSITRON EMISSION TOMOGRAPHY; PYRIDOXINE DEPENDENT SEIZURE; PYRIDOXINE RESPONSIVE SEIZURE; REVIEW; SMITH LEMLI OPITZ SYNDROME; SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SUPPLEMENTATION; TEMPORAL LOBE EPILEPSY; UREA CYCLE DISORDER; CHILD; COMPLICATION; METABOLISM;

AUTISM SPECTRUM DISORDER; CHILD; EPILEPSY; HUMANS; METABOLIC DISEASES; MITOCHONDRIAL DISEASES;

EID: 84937516406     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2014.08.134     Document Type: Review

References (215)

1. APA Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
2. Developmental Disabilities Monitoring Network Surveillance Year Principal I, Centers for Disease C, Prevention. Prevalence of autism spectrum disorder among children aged 8years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 2014, 63:1-21.
3. Chaidez V., Hansen R.L., Hertz-Picciotto I. Gastrointestinal problems in children with autism, developmental delays or typical development. J Autism Dev Disord 2013, 44:1117-1127.
4. Frye R.E., Rossignol D., Casanova M.F., Brown G.L., Martin V., Edelson S., et al. A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. Front Public Health 2013, 1:31.
5. Taurines R., Schwenck C., Westerwald E., Sachse M., Siniatchkin M., Freitag C. ADHD and autism: differential diagnosis or overlapping traits? A selective review. Atten Defic Hyperact Disord 2012, 4:115-139.
6. Sukhodolsky D.G., Bloch M.H., Panza K.E., Reichow B. Cognitive-behavioral therapy for anxiety in children with high-functioning autism: a meta-analysis. Pediatrics 2013, 132:e1341-e1350.
7. Angelidou A., Alysandratos K.D., Asadi S., Zhang B., Francis K., Vasiadi M., et al. Brief report: "allergic symptoms" in children with autism spectrum disorders. More than meets the eye?. J Autism Dev Disord 2011, 41:1579-1585.
8. Tuchman R., Rapin I. Epilepsy in autism. Lancet Neurol 2002, 1:352-358.
9. Deykin E.Y., MacMahon B. The incidence of seizures among children with autistic symptoms. Am J Psychiatry 1979, 136:1310-1312.
10. Volkmar F.R., Nelson D.S. Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry 1990, 29:127-129.
11. Danielsson S., Gillberg I.C., Billstedt E., Gillberg C., Olsson I. Epilepsy in young adults with autism: a prospective population-based follow-up study of 120 individuals diagnosed in childhood. Epilepsia 2005, 46:918-923.
12. Hara H. Autism and epilepsy: a retrospective follow-up study. Brain Dev 2007, 29:486-490.
13. Sansa G., Carlson C., Doyle W., Weiner H.L., Bluvstein J., Barr W., et al. Medically refractory epilepsy in autism. Epilepsia 2011, 52:1071-1075.
14. Gilby K.L., O'Brien T.J. Epilepsy, autism, and neurodevelopment: kindling a shared vulnerability?. Epilepsy Behav 2013, 26:370-374.
15. Tuchman R. Autism and social cognition in epilepsy: implications for comprehensive epilepsy care. Curr Opin Neurol 2013, 26:214-218.
16. Rossignol D.A., Frye R.E. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry 2012, 17:389-401.
17. Schaefer G.B., Mendelsohn N.J., Professional P., Guidelines C. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet Med 2013, 15:399-407.
18. Tuchman R., Hirtz D., Mamounas L.A. NINDS epilepsy and autism spectrum disorders workshop report. Neurology 2013, 81:1630-1636.
19. Murdoch J.D., State M.W. Recent developments in the genetics of autism spectrum disorders. Curr Opin Genet Dev 2013, 23:310-315.
20. Frye R.E., Sequeira J.M., Quadros E.V., James S.J., Rossignol D.A. Cerebral folate receptor autoantibodies in autism spectrum disorder. Mol Psychiatry 2013, 18:369-381.
21. Rossignol D., Frye R.E. Folate receptor alpha autoimmunity and cerebral folate deficiency in autism spectrum disorders. J Pediatr Biochem 2012, 2:263-271.
22. Tierney E., Bukelis I., Thompson R.E., Ahmed K., Aneja A., Kratz L., et al. Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:666-668.
23. Novarino G., El-Fishawy P., Kayserili H., Meguid N.A., Scott E.M., Schroth J., et al. Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science 2012, 338:394-397.
24. Zecavati N., Spence S.J. Neurometabolic disorders and dysfunction in autism spectrum disorders. Curr Neurol Neurosci Rep 2009, 9:129-136.
25. Rossignol D., Frye R.E. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry 2012, 17:290-314.
26. Frye R.E., Rossignol D.A. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res 2011, 69:41R-47R.
27. Frye R.E., Rossignol D. Metabolic disorders and abnormalities associated with autism spectrum disorder. J Pediatr Biochem 2012, 2:181-191.
28. Manji H., Kato T., Di Prospero N.A., Ness S., Beal M.F., Krams M., et al. Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci 2012, 13:293-307.
29. Anglin R.E., Garside S.L., Tarnopolsky M.A., Mazurek M.F., Rosebush P.I. The psychiatric manifestations of mitochondrial disorders: a case and review of the literature. J Clin Psychiatry 2012, 73:506-512.
30. Kang H.C., Lee Y.M., Kim H.D. Mitochondrial disease and epilepsy. Brain Dev 2013, 35:757-761.
31. Kunz W.S. The role of mitochondria in epileptogenesis. Curr Opin Neurol 2002, 15:179-184.
32. Kudin A.P., Zsurka G., Elger C.E., Kunz W.S. Mitochondrial involvement in temporal lobe epilepsy. Exp Neurol 2009, 218:326-332.
33. Ghanizadeh A., Berk M., Farrashbandi H., Alavi Shoushtari A., Villagonzalo K.A. Targeting the mitochondrial electron transport chain in autism, a systematic review and synthesis of a novel therapeutic approach. Mitochondrion 2013, 13:515-519.
34. Kerr D.S. Review of clinical trials for mitochondrial disorders: 1997-2012. Neurotherapeutics 2013, 10:307-319.
35. Poo-Arguelles P., Arias A., Vilaseca M.A., Ribes A., Artuch R., Sans-Fito A., et al. X-linked creatine transporter deficiency in two patients with severe mental retardation and autism. J Inherit Metab Dis 2006, 29:220-223.
36. Longo N., Ardon O., Vanzo R., Schwartz E., Pasquali M. Disorders of creatine transport and metabolism. Am J Med Genet C Semin Med Genet 2011, 157C:72-78.
37. Schulze A. Creatine deficiency syndromes. Mol Cell Biochem 2003, 244:143-150.
38. van Karnebeek C.D., Stockler S. Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review. Mol Genet Metab 2012, 105:368-381.
39. Anselm I.A., Alkuraya F.S., Salomons G.S., Jakobs C., Fulton A.B., Mazumdar M., et al. X-linked creatine transporter defect: a report on two unrelated boys with a severe clinical phenotype. J Inherit Metab Dis 2006, 29:214-219.
40. Sikora D.M., Pettit-Kekel K., Penfield J., Merkens L.S., Steiner R.D. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A 2006, 140:1511-1518.
41. Bukelis I., Porter F.D., Zimmerman A.W., Tierney E. Smith-Lemli-Opitz syndrome and autism spectrum disorder. Am J Psychiatry 2007, 164:1655-1661.
42. Martin A., Koenig K., Scahill L., Tierney E., Porter F.D., Nwokoro N.A. Smith-Lemli-Opitz syndrome. J Am Acad Child Adolesc Psychiatry 2001, 40:506-507.
43. Elias E.R., Irons M.B., Hurley A.D., Tint G.S., Salen G. Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS). Am J Med Genet 1997, 68:305-310.
44. Irons M., Elias E.R., Abuelo D., Bull M.J., Greene C.L., Johnson V.P., et al. Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. Am J Med Genet 1997, 68:311-314.
45. Nwokoro N.A., Mulvihill J.J. Cholesterol and bile acid replacement therapy in children and adults with Smith-Lemli-Opitz (SLO/RSH) syndrome. Am J Med Genet 1997, 68:315-321.
46. Aneja A., Tierney E. Autism: the role of cholesterol in treatment. Int Rev Psychiatry 2008, 20:165-170.
47. Frustaci A., Neri M., Cesario A., Adams J.B., Domenici E., Dalla Bernardina B., et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med 2012, 52:2128-2141.
48. Boris M., Goldblatt A., Galanko J., James S.J. Association of MTHFR gene variants with autism. J Am Phys Surg 2004, 9:106-108.
49. Mohammad N.S., Jain J.M., Chintakindi K.P., Singh R.P., Naik U., Akella R.R. Aberrations in folate metabolic pathway and altered susceptibility to autism. Psychiatr Genet 2009, 19:171-176.
50. Guo T., Chen H., Liu B., Ji W., Yang C. Methylenetetrahydrofolate reductase polymorphisms C677T and risk of autism in the Chinese Han population. Genet Test Mol Biomarkers 2012, 16:968-973.
51. Schmidt R.J., Tancredi D.J., Ozonoff S., Hansen R.L., Hartiala J., Allayee H., et al. Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study. Am J Clin Nutr 2012, 96:80-89.
52. Liu X., Solehdin F., Cohen I.L., Gonzalez M.G., Jenkins E.C., Lewis M.E., et al. Population- and family-based studies associate the MTHFR gene with idiopathic autism in simplex families. J Autism Dev Disord 2011, 41:938-944.
53. Goin-Kochel R.P., Porter A.E., Peters S.U., Shinawi M., Sahoo T., Beaudet A.L. The MTHFR 677C→T polymorphism and behaviors in children with autism: exploratory genotype-phenotype correlations. Autism Res 2009, 2:98-108.
54. Pasca S.P., Dronca E., Kaucsar T., Craciun E.C., Endreffy E., Ferencz B.K., et al. One carbon metabolism disturbances and the C677T MTHFR gene polymorphism in children with autism spectrum disorders. J Cell Mol Med 2009, 13:4229-4238.
55. James S.J., Melnyk S., Jernigan S., Cleves M.A., Halsted C.H., Wong D.H., et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:947-956.
56. Pu D., Shen Y., Wu J. Association between MTHFR gene polymorphisms and the risk of autism spectrum disorders: a meta-analysis. Autism Res 2013, 6:384-392.
57. Adams M., Lucock M., Stuart J., Fardell S., Baker K., Ng X. Preliminary evidence for involvement of the folate gene polymorphism 19bp deletion-DHFR in occurrence of autism. Neurosci Lett 2007, 422:24-29.
58. Ramaekers V.T., Rothenberg S.P., Sequeira J.M., Opladen T., Blau N., Quadros E.V., et al. Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N Engl J Med 2005, 352:1985-1991.
59. Ramaekers V.T., Blau N., Sequeira J.M., Nassogne M.C., Quadros E.V. Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits. Neuropediatrics 2007, 38:276-281.
60. Ramaekers V.T., Blau N. Cerebral folate deficiency. Dev Med Child Neurol 2004, 46:843-851.
61. Wollack J.B., Makori B., Ahlawat S., Koneru R., Picinich S.C., Smith A., et al. Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. J Neurochem 2008, 104:1494-1503.
62. Allen R.J., DiMauro S., Coulter D.L., Papadimitriou A., Rothenberg S.P. Kearns-Sayre syndrome with reduced plasma and cerebrospinal fluid folate. Ann Neurol 1983, 13:679-682.
63. Pineda M., Ormazabal A., Lopez-Gallardo E., Nascimento A., Solano A., Herrero M.D., et al. Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion. Ann Neurol 2006, 59:394-398.
64. Ramaekers V.T., Weis J., Sequeira J.M., Quadros E.V., Blau N. Mitochondrial complex I encephalomyopathy and cerebral 5-methyltetrahydrofolate deficiency. Neuropediatrics 2007, 38:184-187.
65. Hasselmann O., Blau N., Ramaekers V.T., Quadros E.V., Sequeira J.M., Weissert M. Cerebral folate deficiency and CNS inflammatory markers in Alpers disease. Mol Genet Metab 2010, 99:58-61.
66. Perez-Duenas B., Ormazabal A., Toma C., Torrico B., Cormand B., Serrano M., et al. Cerebral folate deficiency syndromes in childhood: clinical, analytical, and etiologic aspects. Arch Neurol 2011, 68:615-621.
67. Garcia-Cazorla A., Quadros E.V., Nascimento A., Garcia-Silva M.T., Briones P., Montoya J., et al. Mitochondrial diseases associated with cerebral folate deficiency. Neurology 2008, 70:1360-1362.
68. Shoffner J., Hyams L., Langley G.N., Cossette S., Mylacraine L., Dale J., et al. Fever plus mitochondrial disease could be risk factors for autistic regression. J Child Neurol 2010, 25:429-434.
69. Frye R.E., Naviaux R.K. Autistic disorder with complex IV overactivity: a new mitochondrial syndrome. J Pediatr Neurol 2011, 9:427-434.
70. Ramaekers V.T., Quadros E.V., Sequeira J.M. Role of folate receptor autoantibodies in infantile autism. Mol Psychiatry 2013, 18:270-271.
71. Moretti P., Sahoo T., Hyland K., Bottiglieri T., Peters S., del Gaudio D., et al. Cerebral folate deficiency with developmental delay, autism, and response to folinic acid. Neurology 2005, 64:1088-1090.
72. Basura G.J., Hagland S.P., Wiltse A.M., Gospe S.M. Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63 North American cases submitted to a patient registry. Eur J Pediatr 2009, 168:697-704.
73. Gupta V.K., Mishra D., Mathur I., Singh K.K. Pyridoxine-dependent seizures: a case report and a critical review of the literature. J Paediatr Child Health 2001, 37:592-596.
74. Mills P.B., Struys E., Jakobs C., Plecko B., Baxter P., Baumgartner M., et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006, 12:307-309.
75. Plecko B., Paul K., Paschke E., Stoeckler-Ipsiroglu S., Struys E., Jakobs C., et al. Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat 2007, 28:19-26.
76. Gospe S.M. Pyridoxine-dependent seizures: findings from recent studies pose new questions. Pediatr Neurol 2002, 26:181-185.
77. Gospe S.M., Olin K.L., Keen C.L. Reduced GABA synthesis in pyridoxine-dependent seizures. Lancet 1994, 343:1133-1134.
78. Bankier A., Turner M., Hopkins I.J. Pyridoxine dependent seizures-a wider clinical spectrum. Arch Dis Child 1983, 58:415-418.
79. Coker S.B. Postneonatal vitamin B6-dependent epilepsy. Pediatrics 1992, 90:221-223.
80. Goutieres F., Aicardi J. Atypical presentations of pyridoxine-dependent seizures: a treatable cause of intractable epilepsy in infants. Ann Neurol 1985, 17:117-120.
81. Haenggeli C.A., Girardin E., Paunier L. Pyridoxine-dependent seizures, clinical and therapeutic aspects. Eur J Pediatr 1991, 150:452-455.
82. Krishnamoorthy K.S. Pyridoxine-dependency seizure: report of a rare presentation. Ann Neurol 1983, 13:103-104.
83. Mikati M.A., Trevathan E., Krishnamoorthy K.S., Lombroso C.T. Pyridoxine-dependent epilepsy: EEG investigations and long-term follow-up. Electroencephalogr Clin Neurophysiol 1991, 78:215-221.
84. Baxter P. Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK. Arch Dis Child 1999, 81:431-433.
85. Martineau J., Barthelemy C., Garreau B., Lelord G. Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry 1985, 20:467-478.
86. Mousain-Bosc M., Roche M., Polge A., Pradal-Prat D., Rapin J., Bali J.P. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnes Res 2006, 19:53-62.
87. Lelord G., Callaway E., Muh J.P. Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children. Acta Vitaminol Enzymol 1982, 4:27-44.
88. Lelord G., Muh J.P., Barthelemy C., Martineau J., Garreau B., Callaway E. Effects of pyridoxine and magnesium on autistic symptoms-initial observations. J Autism Dev Disord 1981, 11:219-230.
89. Nye C., Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev 2005, CD003497.
90. Rossignol D.A. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry 2009, 21:213-236.
91. Burd L., Stenehjem A., Franceschini L.A., Kerbeshian J. A 15-year follow-up of a boy with pyridoxine (vitamin B6)-dependent seizures with autism, breath holding, and severe mental retardation. J Child Neurol 2000, 15:763-765.
92. Zaffanello M., Zamboni G., Fontana E., Zoccante L., Tato L. A case of partial biotinidase deficiency associated with autism. Child Neuropsychol 2003, 9:184-188.
93. Celestino-Soper P.B., Violante S., Crawford E.L., Luo R., Lionel A.C., Delaby E., et al. A common X-linked inborn error of carnitine biosynthesis may be a risk factor for nondysmorphic autism. Proc Natl Acad Sci U S A 2012, 109:7974-7981.
94. Filipek P.A., Juranek J., Nguyen M.T., Cummings C., Gargus J.J. Relative carnitine deficiency in autism. J Autism Dev Disord 2004, 34:615-623.
95. Palmieri L., Persico A.M. Mitochondrial dysfunction in autism spectrum disorders: cause or effect?. Biochim Biophys Acta 2010, 1797:1130-1137.
96. Frye R.E., Melnyk S., Macfabe D.F. Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder. Transl Psychiatry 2013, 3:e220.
97. Macfabe D.F. Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders. Microb Ecol Health Dis 2012, 23.
98. Jakobs C., Bojasch M., Monch E., Rating D., Siemes H., Hanefeld F. Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities. The probability of a new inborn error of metabolism. Clin Chim Acta 1981, 111:169-178.
99. Pearl P.L., Gibson K.M., Quezado Z., Dustin I., Taylor J., Trzcinski S., et al. Decreased GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase deficiency. Neurology 2009, 73:423-429.
100. Knerr I., Gibson K.M., Jakobs C., Pearl P.L. Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients. CNS Spectr 2008, 13:598-605.
101. Pearl P.L., Gibson K.M. Clinical aspects of the disorders of GABA metabolism in children. Curr Opin Neurol 2004, 17:107-113.
102. Pearl P.L., Novotny E.J., Acosta M.T., Jakobs C., Gibson K.M. Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol 2003, 54(Suppl. 6):S73-S80.
103. Pearl P.L., Gibson K.M., Acosta M.T., Vezina L.G., Theodore W.H., Rogawski M.A., et al. Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 2003, 60:1413-1417.
104. Jurecka A., Zikanova M., Tylki-Szymanska A., Krijt J., Bogdanska A., Gradowska W., et al. Clinical, biochemical and molecular findings in seven Polish patients with adenylosuccinate lyase deficiency. Mol Genet Metab 2008, 94:435-442.
105. Spiegel E.K., Colman R.F., Patterson D. Adenylosuccinate lyase deficiency. Mol Genet Metab 2006, 89:19-31.
106. Gitiaux C., Ceballos-Picot I., Marie S., Valayannopoulos V., Rio M., Verrieres S., et al. Misleading behavioural phenotype with adenylosuccinate lyase deficiency. Eur J Hum Genet 2009, 17:133-136.
107. Page T. Metabolic approaches to the treatment of autism spectrum disorders. J Autism Dev Disord 2000, 30:463-469.
108. Page T., Yu A., Fontanesi J., Nyhan W.L. Developmental disorder associated with increased cellular nucleotidase activity. Proc Natl Acad Sci U S A 1997, 94:11601-11606.
109. Williams R.A., Mamotte C.D., Burnett J.R. Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochem Rev 2008, 29:31-41.
110. Baieli S., Pavone L., Meli C., Fiumara A., Coleman M. Autism and phenylketonuria. J Autism Dev Disord 2003, 33:201-204.
111. Martynyuk A.E., Ucar D.A., Yang D.D., Norman W.M., Carney P.R., Dennis D.M., et al. Epilepsy in phenylketonuria: a complex dependence on serum phenylalanine levels. Epilepsia 2007, 48:1143-1150.
112. Gross P.T., Berlow S., Schuett V.E., Fariello R.G. EEG in phenylketonuria. Attempt to establish clinical importance of EEG changes. Arch Neurol 1981, 38:122-126.
113. Boccuto L., Chen C.F., Pittman A.R., Skinner C.D., McCartney H.J., Jones K., et al. Decreased tryptophan metabolism in patients with autism spectrum disorders. Mol Autism 2013, 4:16.
114. Egawa J., Watanabe Y., Endo T., Someya T. Association of rs2129575 in the tryptophan hydroxylase 2 gene with clinical phenotypes of autism spectrum disorders. Psychiatry Clin Neurosci 2013, 67:457-458.
115. Yang S.Y., Yoo H.J., Cho I.H., Park M., Kim S.A. Association with tryptophan hydroxylase 2 gene polymorphisms and autism spectrum disorders in Korean families. Neurosci Res 2012, 73:333-336.
116. Bragatti J.A., Bandeira I.C., de Carvalho A.M., Abujamra A.L., Leistner-Segal S., Bianchin M.M. Tryptophan hydroxylase 2 (TPH2) gene polymorphisms and psychiatric comorbidities in temporal lobe epilepsy. Epilepsy Behav 2014, 32:59-63.
117. Arbatova J., D'Amato E., Vaarmann A., Zharkovsky A., Reeben M. Reduced serotonin and 3-hydroxyanthranilic acid levels in serum of cystatin B-deficient mice, a model system for progressive myoclonus epilepsy. Epilepsia 2005, 46(Suppl. 5):49-51.
118. Vaarmann A., Kaasik A., Zharkovsky A. Altered tryptophan metabolism in the brain of cystatin B-deficient mice: a model system for progressive myoclonus epilepsy. Epilepsia 2006, 47:1650-1654.
119. Gorker I., Tuzun U. Autistic-like findings associated with a urea cycle disorder in a 4-year-old girl. J Psychiatry Neurosci 2005, 30:133-135.
120. Serrano M., Martins C., Perez-Duenas B., Gomez-Lopez L., Murgui E., Fons C., et al. Neuropsychiatric manifestations in late-onset urea cycle disorder patients. J Child Neurol 2010, 25:352-358.
121. Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab 2010, 100(Suppl. 1):S3-S12.
122. Rossignol D.A., Frye R.E. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry 2012, 17:290-314.
123. Frye R.E. Biomarker of abnormal energy metabolism in children with autism spectrum disorder. N Am J Med Sci 2012, 5:141-147.
124. Giulivi C., Zhang Y.F., Omanska-Klusek A., Ross-Inta C., Wong S., Hertz-Picciotto I., et al. Mitochondrial dysfunction in autism. JAMA 2010, 304:2389-2396.
125. Napoli E., Wong S., Hertz-Picciotto I., Giulivi C. Deficits in bioenergetics and impaired immune response in granulocytes from children with autism. Pediatrics 2014, 133:e1405-e1410.
126. Rose S., Melnyk S., Pavliv O., Bai S., Nick T.G., Frye R.E., et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl Psychiatry 2012, 2:e134.
127. Chauhan A., Gu F., Essa M.M., Wegiel J., Kaur K., Brown W.T., et al. Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism. J Neurochem 2011, 117:209-220.
128. Tang G., Gutierrez Rios P., Kuo S.H., Akman H.O., Rosoklija G., Tanji K., et al. Mitochondrial abnormalities in temporal lobe of autistic brain. Neurobiol Dis 2013, 54:349-361.
129. Anitha A., Nakamura K., Thanseem I., Yamada K., Iwayama Y., Toyota T., et al. Brain region-specific altered expression and association of mitochondria-related genes in autism. Mol Autism 2012, 3:12.
130. Anitha A., Nakamura K., Thanseem I., Matsuzaki H., Miyachi T., Tsujii M., et al. Downregulation of the expression of mitochondrial electron transport complex genes in autism brains. Brain Pathol 2013, 23:294-302.
131. Rossignol D.A., Frye R.E. Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism. Front Physiol 2014, 5:150.
132. Kriaucionis S., Paterson A., Curtis J., Guy J., Macleod N., Bird A. Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Mol Cell Biol 2006, 26:5033-5042.
133. Graf W.D., Marin-Garcia J., Gao H.G., Pizzo S., Naviaux R.K., Markusic D., et al. Autism associated with the mitochondrial DNA G8363A transfer RNA(Lys) mutation. J Child Neurol 2000, 15:357-361.
134. Rose S., Frye R.E., Slattery J., Wynne R., Tippett M., Pavliv O., et al. Oxidative stress induces mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines in a well-matched case control cohort. PLoS One 2014, 9:e85436.
135. Rose S., Frye R.E., Slattery J., Wynne R., Tippett M., Melnyk S., et al. Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines. Transl Psychiatry 2014, 4:e377.
136. Minshew N.J., Goldstein G., Dombrowski S.M., Panchalingam K., Pettegrew J.W. A preliminary 31P MRS study of autism: evidence for undersynthesis and increased degradation of brain membranes. Biol Psychiatry 1993, 33:762-773.
137. Mostafa G.A., El-Gamal H.A., El-Wakkad A.S.E., El-Shorbagy O.E., Hamza M.M. Polyunsaturated fatty acids, carnitine and lactate as biological markers of brain energy in autistic children. Int J Child Neuropsychiatry 2005, 2:179-188.
138. Frye R.E., Delatorre R., Taylor H., Slattery J., Melnyk S., Chowdhury N., et al. Redox metabolism abnormalities in autistic children associated with mitochondrial disease. Transl Psychiatry 2013, 3:e273.
139. Fillano J.J., Goldenthal M.J., Rhodes C.H., Marin-Garcia J. Mitochondrial dysfunction in patients with hypotonia, epilepsy, autism, and developmental delay: HEADD syndrome. J Child Neurol 2002, 17:435-439.
140. Filipek P.A., Juranek J., Smith M., Mays L.Z., Ramos E.R., Bocian M., et al. Mitochondrial dysfunction in autistic patients with 15q inverted duplication. Ann Neurol 2003, 53:801-804.
141. Poling J.S., Frye R.E., Shoffner J., Zimmerman A.W. Developmental regression and mitochondrial dysfunction in a child with autism. J Child Neurol 2006, 21:170-172.
142. Grosser E., Hirt U., Janc O.A., Menzfeld C., Fischer M., Kempkes B., et al. Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome. Neurobiol Dis 2012, 48:102-114.
143. Gibson J.H., Slobedman B., NH K., Williamson S.L., Minchenko D., El-Osta A., et al. Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain. BMC Neurosci 2010, 11:53.
144. Condie J., Goldstein J., Wainwright M.S. Acquired microcephaly, regression of milestones, mitochondrial dysfunction, and episodic rigidity in a 46, XY male with a de novo MECP2 gene mutation. J Child Neurol 2010, 25:633-636.
145. Napoli E., Ross-Inta C., Wong S., Hung C., Fujisawa Y., Sakaguchi D., et al. Mitochondrial dysfunction in Pten haplo-insufficient mice with social deficits and repetitive behavior: interplay between Pten and p53. PLoS One 2012, 7:e42504.
146. Frye R.E. Mitochondrial disease in 22q13 duplication syndrome. J Child Neurol 2012, 27:942-949.
147. Frye R.E. 15q11.2-13 duplication, mitochondrial dysfunction, and developmental disorders. J Child Neurol 2009, 24:1316-1320.
148. Su H., Fan W., Coskun P.E., Vesa J., Gold J.A., Jiang Y.H., et al. Mitochondrial dysfunction in CA1 hippocampal neurons of the UBE3A deficient mouse model for Angelman syndrome. Neurosci Lett 2011, 487:129-133.
149. Schuelke M., Krude H., Finckh B., Mayatepek E., Janssen A., Schmelz M., et al. Septo-optic dysplasia associated with a new mitochondrial cytochrome b mutation. Ann Neurol 2002, 51:388-392.
150. Pagano G., Castello G. Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv Exp Med Biol 2012, 724:291-299.
151. Pallardo F.V., Lloret A., Lebel M., d'Ischia M., Cogger V.C., Le Couteur D.G., et al. Mitochondrial dysfunction in some oxidative stress-related genetic diseases: ataxia-telangiectasia, Down syndrome, Fanconi anaemia and Werner syndrome. Biogerontology 2010, 11:401-419.
152. De Angelis M., Piccolo M., Vannini L., Siragusa S., De Giacomo A., Serrazzanetti D.I., et al. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS One 2013, 8:e76993.
153. Macfabe D. Autism: metabolism, mitochondria, and the microbiome. Glob Adv Health Med 2013, 2:52-66.
154. Ames A. CNS energy metabolism as related to function. Brain Res Brain Res Rev 2000, 34:42-68.
155. Mattson M.P., Liu D. Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromolecular Med 2002, 2:215-231.
156. Chen H., Chan D.C. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 2009, 18:R169-R176.
157. Li Z., Okamoto K., Hayashi Y., Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004, 119:873-887.
158. Anderson M.P., Hooker B.S., Herbert M.R. Bridging from cells to cognition in autism pathophysiology: biological pathways to defective brain function and plasticity. Am J Biochem Biotechnol 2008, 4:167-176.
159. Orekhova E.V., Stroganova T.A., Nygren G., Tsetlin M.M., Posikera I.N., Gillberg C., et al. Excess of high frequency electroencephalogram oscillations in boys with autism. Biol Psychiatry 2007, 62:1022-1029.
160. Herlenius E., Lagercrantz H. Development of neurotransmitter systems during critical periods. Exp Neurol 2004, 190(Suppl. 1):S8-S21.
161. Huttenlocher P.R., Dabholkar A.S. Regional differences in synaptogenesis in human cerebral cortex. J Comp Neurol 1997, 387:167-178.
162. Groeschel S., Vollmer B., King M.D., Connelly A. Developmental changes in cerebral grey and white matter volume from infancy to adulthood. Int J Dev Neurosci 2010, 28:481-489.
163. Rowley N.M., Madsen K.K., Schousboe A., Steve White H. Glutamate and GABA synthesis, release, transport and metabolism as targets for seizure control. Neurochem Int 2012, 61:546-558.
164. Lason W., Chlebicka M., Rejdak K. Research advances in basic mechanisms of seizures and antiepileptic drug action. Pharmacol Rep 2013, 65:787-801.
165. Pastore A., Federici G., Bertini E., Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta 2003, 333:19-39.
166. Aguiar C.C., Almeida A.B., Araujo P.V., de Abreu R.N., Chaves E.M., do Vale O.C., et al. Oxidative stress and epilepsy: literature review. Oxid Med Cell Longev 2012, 2012:795259.
167. Grosso C., Valentao P., Ferreres F., Andrade P.B. The use of flavonoids in central nervous system disorders. Curr Med Chem 2013, 20:4694-4719.
168. Azam F., Prasad M.V., Thangavel N. Targeting oxidative stress component in the therapeutics of epilepsy. Curr Top Med Chem 2012, 12:994-1007.
169. Milder J., Patel M. Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res 2012, 100:295-303.
170. Scheck A.C., Abdelwahab M.G., Fenton K.E., Stafford P. The ketogenic diet for the treatment of glioma: insights from genetic profiling. Epilepsy Res 2012, 100:327-337.
171. Xu D., Miller S.D., Koh S. Immune mechanisms in epileptogenesis. Front Cell Neurosci 2013, 7:195.
172. Gesundheit B., Rosenzweig J.P., Naor D., Lerer B., Zachor D.A., Prochazka V., et al. Immunological and autoimmune considerations of autism spectrum disorders. J Autoimmun 2013, 44:1-7.
173. Connolly A.M., Chez M.G., Pestronk A., Arnold S.T., Mehta S., Deuel R.K. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr 1999, 134:607-613.
174. Connolly A.M., Chez M., Streif E.M., Keeling R.M., Golumbek P.T., Kwon J.M., et al. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatry 2006, 59:354-363.
175. Derecki N.C., Cronk J.C., Lu Z., Xu E., Abbott S.B., Guyenet P.G., et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012, 484:105-109.
176. Boulanger L.M., Shatz C.J. Immune signalling in neural development, synaptic plasticity and disease. Nat Rev Neurosci 2004, 5:521-531.
177. Gargus J.J. Genetic calcium signaling abnormalities in the central nervous system: seizures, migraine, and autism. Ann N Y Acad Sci 2009, 1151:133-156.
178. Schmunk G., Gargus J.J. Channelopathy pathogenesis in autism spectrum disorders. Front Genet 2013, 4.
179. Splawski I., Timothy K.W., Sharpe L.M., Decher N., Kumar P., Bloise R., et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004, 119:19-31.
180. Rizzuto R., Bernardi P., Pozzan T. Mitochondria as all-round players of the calcium game. J Physiol 2000, 529(Pt 1):37-47.
181. Kaufman R.J., Malhotra J.D. Calcium trafficking integrates endoplasmic reticulum function with mitochondrial bioenergetics. Biochim Biophys Acta 1843, 2014:2233-2239.
182. van Vliet A.R., Verfaillie T., Agostinis P. New functions of mitochondria associated membranes in cellular signaling. Biochim Biophys Acta 1843, 2014:2253-2262.
183. Geier D.A., Kern J.K., Davis G., King P.G., Adams J.B., Young J.L., et al. A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Med Sci Monit 2011, 17:I15-I23.
184. Fahmy S.F., El-hamamsy M.H., Zaki O.K., Badary O.A. l-Carnitine supplementation improves the behavioral symptoms in autistic children. Res Autism Spectr Disord 2013, 7:159-166.
185. Pastural E., Ritchie S., Lu Y., Jin W., Kavianpour A., Khine Su-Myat K., et al. Novel plasma phospholipid biomarkers of autism: mitochondrial dysfunction as a putative causative mechanism. Prostaglandins Leukot Essent Fatty Acids 2009, 81:253-264.
186. Gargus J.J., Lerner M.A. Familial autism with primary carnitine deficiency, sudden death, hypotonia and hypochromic anemia. Am J Hum Genet 1997, 61:A98.
187. Gargus J.J., Imtiaz F. Mitochondrial energy-deficient endophenotype in autism. Am J Biochem Biotech 2008, 4:198-207.
188. Ezugha H., Goldenthal M., Valencia I., Anderson C.E., Legido A., Marks H. 5q14.3 deletion manifesting as mitochondrial disease and autism: case report. J Child Neurol 2010, 25:1232-1235.
189. Adams J.B., Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med 2004, 10:1033-1039.
190. Adams J.B., Audhya T., McDonough-Means S., Rubin R.A., Quig D., Geis E., et al. Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatr 2011, 11:111.
191. Dolske M.C., Spollen J., McKay S., Lancashire E., Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993, 17:765-774.
192. Frye R.E., Melnyk S., Fuchs G., Reid T., Jernigan S., Pavliv O., et al. Effectiveness of methylcobalamin and folinic acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status. Autism Res Treat 2013, 2013:609705.
193. James S.J., Melnyk S., Fuchs G., Reid T., Jernigan S., Pavliv O., et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr 2009, 89:425-430.
194. Nakano K., Noda N., Tachikawa E., Urano M.A.N., Takazawa M., Nakayama T., et al. A preliminary study of methylcobalamin therapy in autism. J Tokyo Women's Med Univ 2005, 75:64-69.
195. Ghanizadeh A., Derakhshan N. N-acetylcysteine for treatment of autism, a case report. J Res Med Sci 2012, 17:985-987.
196. Ghanizadeh A., Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry 2013, 13:196.
197. Hardan A.Y., Fung L.K., Libove R.A., Obukhanych T.V., Nair S., Herzenberg L.A., et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012, 71:956-961.
198. Gvozdjakova A., Kucharska J., Ostatnikova D., Babinska K., Nakladal D., Crane F.L. Ubiquinol improves symptoms in children with autism. Oxid Med Cell Longev 2014, 2014:798957.
199. Chez M.G., Buchanan C.P., Aimonovitch M.C., Becker M., Schaefer K., Black C., et al. Double-blind, placebo-controlled study of l-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol 2002, 17:833-837.
200. Foley K.A., Ossenkopp K.P., Kavaliers M., Macfabe D.F. Pre- and neonatal exposure to lipopolysaccharide or the enteric metabolite, propionic acid, alters development and behavior in adolescent rats in a sexually dimorphic manner. PLoS One 2014, 9:e87072.
201. Foley K.A., Macfabe D.F., Vaz A., Ossenkopp K.P., Kavaliers M. Sexually dimorphic effects of prenatal exposure to propionic acid and lipopolysaccharide on social behavior in neonatal, adolescent, and adult rats: implications for autism spectrum disorders. Int J Dev Neurosci 2014, 39:68-78.
202. Ahn Y., Narous M., Tobias R., Rho J.M., Mychasiuk R. The ketogenic diet modifies social and metabolic alterations identified in the prenatal valproic acid model of autism spectrum disorder. Dev Neurosci 2014, 36:371-380.
203. Gilby K.L. A new rat model for vulnerability to epilepsy and autism spectrum disorders. Epilepsia 2008, 49(Suppl. 8):108-110.
204. Ruskin D.N., Svedova J., Cote J.L., Sandau U., Rho J.M., Kawamura M., et al. Ketogenic diet improves core symptoms of autism in BTBR mice. PLoS One 2013, 8:e65021.
205. Mantis J.G., Meidenbauer J.J., Zimick N.C., Centeno N.A., Seyfried T.N. Glucose reduces the anticonvulsant effects of the ketogenic diet in EL mice. Epilepsy Res 2014, 108:1137-1144.
206. Munnich A., Rotig A., Chretien D., Cormier V., Bourgeron T., Bonnefont J.P., et al. Clinical presentation of mitochondrial disorders in childhood. J Inherit Metab Dis 1996, 19:521-527.
207. Nissenkorn A., Zeharia A., Lev D., Watemberg N., Fattal-Valevski A., Barash V., et al. Neurologic presentations of mitochondrial disorders. J Child Neurol 2000, 15:44-48.
208. Zeviani M., Di Donato S. Mitochondrial disorders. Brain 2004, 127:2153-2172.
209. Chauhan A., Chauhan V. Oxidative stress in autism. Pathophysiology 2006, 13:171-181.
210. Rossignol D.A., Genuis S.J., Frye R.E. Environmental toxicants and autism spectrum disorders: a systematic review. Transl Psychiatry 2014, 4:e360.
211. Sandler R.H., Finegold S.M., Bolte E.R., Buchanan C.P., Maxwell A.P., Vaisanen M.L., et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000, 15:429-435.
212. Finegold S.M., Molitoris D., Song Y., Liu C., Vaisanen M.L., Bolte E., et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 2002, 35:S6-S16.
213. Morava E., van den Heuvel L., Hol F., de Vries M.C., Hogeveen M., Rodenburg R.J., et al. Mitochondrial disease criteria: diagnostic applications in children. Neurology 2006, 67:1823-1826.
214. Smeitink J.A. Mitochondrial disorders: clinical presentation and diagnostic dilemmas. J Inherit Metab Dis 2003, 26:199-207.
215. Ramaekers V.T., Sequeira J.M., Artuch R., Blau N., Temudo T., Ormazabal A., et al. Folate receptor autoantibodies and spinal fluid 5-methyltetrahydrofolate deficiency in Rett syndrome. Neuropediatrics 2007, 38:179-183.